Answers are grounded in this paper and cite their sources.
s and to facilitate the understanding of the relevant chemistry and biochemical pathways. Focusing exemplarily on brain and breast cancer, recent advances spanning 2017 to 2023 in conjugated nanocarriers and small molecule drug conjugates were considered, evaluating the chemical and biological aspects in order to improve accessibility to the field and to bridge chemical and biomedical points of view ultimately guiding future research in FR-targeted cancer therapy and diagnosis.
No takes yet. Share an insight, caveat, or question.
Ahmadi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: